Kiyoshi Yamazaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kiyoshi Yamazaki has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Shunichi Sato
First Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
5 shared publicationsKazuyuki Suzuki
First Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
3 shared publicationsTakeo Madarame
3 shared publicationsAtsushi Nakamura
First Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
2 shared publicationsIchiro Nakadate
2 shared publications- Kazuyuki Suzuki
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan
2 shared publications
Latest Publications
- Open Access
- 1 July 1999
- Published by Wolters Kluwer Health in Hepatology
- Vol. 30 (1) , 71-78
Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis
Eosinophilia is a distinctive feature of primary biliary cirrhosis (PBC), especially in its early stages. Intriguingly, treatment with ursodeoxycholic acid (UDCA) ameliorates eosinophilia as well as liver tests in patients with PBC. It remains unknown, however, whether eosinophils in PBC patients are functionally activated and whether UDCA inhibits eosinophil activation. In the present study, we systematically examined eosinophil dynamics in the blood and liver in patients with stage I to II PBC before and after UDCA treatment. We determined serum concentrations of eosinophil granule proteins (major basic protein [MBP] and eosinophil-derived neurotoxin [EDN]) by radioimmunoassay and quantitated eosinophil degranulation using computer-assisted morphometry after MBP immunohistochemistry. Before UDCA treatment, patients with PBC (n = 25) showed significantly higher circulating eosinophil counts (P < .05) and serum concentrations of MBP (P < .0005) and EDN (P < .02) compared with patients with chronic viral hepatitis (n = 22), autoimmune hepatitis (n = 10), and obstructive jaundice (n = 12). Four-week UDCA treatment significantly reduced blood eosinophil counts (P < .0001) and serum MBP (P < .0001) and EDN (P < .0001) levels in PBC patients. MBP immunohistochemistry and computer-assisted quantitative morphometry showed infiltration and degranulation of eosinophils in the portal tract in patients with PBC and significant reductions in the number of sites and the area occupied by extracellular MBP deposits after UDCA treatment for 2 years (P < .02) but not in placebo-treated patients. Our results suggest that eosinophils in patients with PBC are not only increased in number, but also release granule proteins, and that UDCA treatment inhibits this eosinophil activation/degranulation
- 1 July 1999
- Published by Wolters Kluwer Health in Hepatology
- Vol. 30 (1) , 71-78
Open AccessUrsodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis
Eosinophilia is a distinctive feature of primary biliary cirrhosis (PBC), especially in its early stages. Intriguingly, treatment with ursodeoxycholic acid (UDCA) ameliorates eosinophilia as well as liver tests in patients with PBC. It remains unknown, however, whether eosinophils in PBC patients are functionally activated and whether UDCA inhibits eosinophil activation. In the present study, we systematically examined eosinophil dynamics in the blood and liver in patients with stage I to II PBC before and after UDCA treatment. We determined serum concentrations of eosinophil granule proteins (major basic protein [MBP] and eosinophil-derived neurotoxin [EDN]) by radioimmunoassay and quantitated eosinophil degranulation using computer-assisted morphometry after MBP immunohistochemistry. Before UDCA treatment, patients with PBC (n = 25) showed significantly higher circulating eosinophil counts (P < .05) and serum concentrations of MBP (P < .0005) and EDN (P < .02) compared with patients with chronic viral hepatitis (n = 22), autoimmune hepatitis (n = 10), and obstructive jaundice (n = 12). Four-week UDCA treatment significantly reduced blood eosinophil counts (P < .0001) and serum MBP (P < .0001) and EDN (P < .0001) levels in PBC patients. MBP immunohistochemistry and computer-assisted quantitative morphometry showed infiltration and degranulation of eosinophils in the portal tract in patients with PBC and significant reductions in the number of sites and the area occupied by extracellular MBP deposits after UDCA treatment for 2 years (P < .02) but not in placebo-treated patients. Our results suggest that eosinophils in patients with PBC are not only increased in number, but also release granule proteins, and that UDCA treatment inhibits this eosinophil activation/degranulation
- Open Access
- 1 January 1995
- Published by Japan Society of Hepatology in Kanzo
- Vol. 36 (1) , 1-6
Clinical features of fulminant hepatitis: An etiological analysis.
当教室にて1981年から1993年までの13年間に経験した劇症肝炎40例を対象に,輸血スクリーニング法の確立した時期を考慮して,1989年以前と1990年以降に分けてその成因を比較し,成因ウイルス別にみた臨床像を検討した.成因は,ウイルス性35例,薬剤性1例,自己免疫性4例であり,ウイルスの重感染例は認めなかった.1989年以前はB型68%(輸血後例44%),N型16%であったが,1990年以降はB型20%(輸血後例0%),N型47%とB型の明らかな減少とN型の増加傾向を認めた.C型の臨床像はB型に比して,1)肝炎発生から脳症発現までの期間が長い,2)脳症発現時の総ビリルビン値が高い一方,PT(%)が比較的保たれている,3)血清トランスアミナーゼの低下が遷延している,4) AFPの反応が低い,などの特徴を認めた.N型はB型とC型の中間の臨床像を呈しており,その成因については今後さらに検討が必要と考えられた.
- 1 January 1995
- Published by Japan Society of Hepatology in Kanzo
- Vol. 36 (1) , 1-6
Open AccessClinical features of fulminant hepatitis: An etiological analysis.
当教室にて1981年から1993年までの13年間に経験した劇症肝炎40例を対象に,輸血スクリーニング法の確立した時期を考慮して,1989年以前と1990年以降に分けてその成因を比較し,成因ウイルス別にみた臨床像を検討した.成因は,ウイルス性35例,薬剤性1例,自己免疫性4例であり,ウイルスの重感染例は認めなかった.1989年以前はB型68%(輸血後例44%),N型16%であったが,1990年以降はB型20%(輸血後例0%),N型47%とB型の明らかな減少とN型の増加傾向を認めた.C型の臨床像はB型に比して,1)肝炎発生から脳症発現までの期間が長い,2)脳症発現時の総ビリルビン値が高い一方,PT(%)が比較的保たれている,3)血清トランスアミナーゼの低下が遷延している,4) AFPの反応が低い,などの特徴を認めた.N型はB型とC型の中間の臨床像を呈しており,その成因については今後さらに検討が必要と考えられた.
- Open Access
- 1 January 1993
- Published by Japan Society of Hepatology in Kanzo
- Vol. 34 (8) , 665-671
Autoimmune hepatitis presenting with acute hepatic failure.
重症急性肝炎様の発症を示し,劇症肝炎ならびに亜急性肝炎の経過をたどった自己免疫性肝炎3例を経験し,文献的報告を加えて報告した.症例1:39歳,女性.感冒様症状,全身倦怠感,食欲不振にて発症.γ-gl 3.6g/dl, IgG 2,438mg/dl, ANA640倍,抗DNA抗体160倍,LE test(±).症例2:69歳,女性.嘔気,全身倦怠感にて発症.γ-gl 3.0g/dl, IgG4, 454mg/dl, ANA160倍,抗DNA抗体320倍,LE test(++).症例3:69歳,女性.黄疸,全身倦怠感にて発症.γ-gl 2.8g/dl, IgG 3,603mg/gl, ANA40, 960倍,抗DNA抗体160倍,LE test (+).3症例とも副腎皮質ステロイドの投与および血漿交換等の人工肝補助を施行したが,救命に至らなかった.文献的にも自己免疫性肝炎の急性,重症発症例の報告が認められるが,多くは予後不良の経過を示しており,その発生機序の解明と治療法についての再考が必要と考えられた.
- 1 January 1993
- Published by Japan Society of Hepatology in Kanzo
- Vol. 34 (8) , 665-671
Open AccessAutoimmune hepatitis presenting with acute hepatic failure.
重症急性肝炎様の発症を示し,劇症肝炎ならびに亜急性肝炎の経過をたどった自己免疫性肝炎3例を経験し,文献的報告を加えて報告した.症例1:39歳,女性.感冒様症状,全身倦怠感,食欲不振にて発症.γ-gl 3.6g/dl, IgG 2,438mg/dl, ANA640倍,抗DNA抗体160倍,LE test(±).症例2:69歳,女性.嘔気,全身倦怠感にて発症.γ-gl 3.0g/dl, IgG4, 454mg/dl, ANA160倍,抗DNA抗体320倍,LE test(++).症例3:69歳,女性.黄疸,全身倦怠感にて発症.γ-gl 2.8g/dl, IgG 3,603mg/gl, ANA40, 960倍,抗DNA抗体160倍,LE test (+).3症例とも副腎皮質ステロイドの投与および血漿交換等の人工肝補助を施行したが,救命に至らなかった.文献的にも自己免疫性肝炎の急性,重症発症例の報告が認められるが,多くは予後不良の経過を示しており,その発生機序の解明と治療法についての再考が必要と考えられた.
- Open Access
- 1 January 1986
- Published by Japan Society of Hepatology in Kanzo
- Vol. 27 (9) , 1272-1280
Clinical features of primary biliary cirrhosis. A comparison between symptomatic and asymptomatic patients.
原発性胆汁性肝硬変(PBC) 23例の臨床像を,症候性例(s-PBC) 15例,無症候性例(a-PBC) 8例に分け比較検討した.年齢,観察期間,組織像には差が認められなかった.生化学的検討では,s-PBCはa-PBCに比し,GOT, γ-GTPが有意に高値であった(p<0.05).免疫学的検討では,抗ミトコンドリア抗体高力価例が,s-PBCに有意に高率であった(p<0.05)が,免疫グロブリン値,末梢血リンパ球サブセットに有意差は認められなかった.合併疾患の検討では,Sjögren症候群(SjS)が主たる合併疾患であり,55%に乾燥症状が認められた.同症状はs-PBCに有意に高率に(p<0.05)出現していたが,SjSに特異的とされる抗SS-A, SS-B抗体の陽性例が存在しない点が注目された.乾燥症状の有無によりs-PBC, a-PBCそれぞれの臨床像に有意の差は認められなかった.SjSがPBCの臨床像に影響を与えるか否かについては,SjSの診断が必ずしも容易ではないことから,今後とも充分な検討が必要である.
- 1 January 1986
- Published by Japan Society of Hepatology in Kanzo
- Vol. 27 (9) , 1272-1280
Open AccessClinical features of primary biliary cirrhosis. A comparison between symptomatic and asymptomatic patients.
原発性胆汁性肝硬変(PBC) 23例の臨床像を,症候性例(s-PBC) 15例,無症候性例(a-PBC) 8例に分け比較検討した.年齢,観察期間,組織像には差が認められなかった.生化学的検討では,s-PBCはa-PBCに比し,GOT, γ-GTPが有意に高値であった(p<0.05).免疫学的検討では,抗ミトコンドリア抗体高力価例が,s-PBCに有意に高率であった(p<0.05)が,免疫グロブリン値,末梢血リンパ球サブセットに有意差は認められなかった.合併疾患の検討では,Sjögren症候群(SjS)が主たる合併疾患であり,55%に乾燥症状が認められた.同症状はs-PBCに有意に高率に(p<0.05)出現していたが,SjSに特異的とされる抗SS-A, SS-B抗体の陽性例が存在しない点が注目された.乾燥症状の有無によりs-PBC, a-PBCそれぞれの臨床像に有意の差は認められなかった.SjSがPBCの臨床像に影響を与えるか否かについては,SjSの診断が必ずしも容易ではないことから,今後とも充分な検討が必要である.
- 1 January 1984
- Published by Japan Society of Hepatology in Kanzo
- Vol. 25 (11) , 1461-1467
A case of primary biliary cirrhosis with Sjoegren's syndrome: Histological evaluation of the pancreas with biopsied specimen.
- 1 January 1984
- Published by Japan Society of Hepatology in Kanzo
- Vol. 25 (11) , 1461-1467
A case of primary biliary cirrhosis with Sjoegren's syndrome: Histological evaluation of the pancreas with biopsied specimen.